Strahlentherapie des Mediastinalen Hodgkin-Lymphoms

Literaturverzeichnis
Crump, M., and Hodgson, D. (2009). Secondary breast cancer in Hodgkin's lymphoma survivors. J Clin Oncol
27, 4229-4231.
Darby, S.C., Cutter, D.J., Boerma, M., Constine, L.S., Fajardo, L.F., Kodama, K., Mabuchi, K., Marks, L.B.,
Mettler, F.A., Pierce, L.J., Trott, K.R., Yeh, E.T., and Shore, R.E. (2010). Radiation-related heart disease:
current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76, 656-665.
De Bruin, M.L., Dorresteijn, L.D., van't Veer, M.B., Krol, A.D., van der Pal, H.J., Kappelle, A.C., Boogerd, W.,
Aleman, B.M., and van Leeuwen, F.E. (2009a). Increased risk of stroke and transient ischemic attack in 5-year
survivors of Hodgkin lymphoma. J Natl Cancer Inst 101, 928-937.
De Bruin, M.L., Sparidans, J., van't Veer, M.B., Noordijk, E.M., Louwman, M.W., Zijlstra, J.M., van den Berg,
H., Russell, N.S., Broeks, A., Baaijens, M.H., Aleman, B.M., and van Leeuwen, F.E. (2009b). Breast cancer risk
in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27, 4239-
4246.
DeVita, V.T., Jr., Serpick, A.A., and Carbone, P.P. (1970). Combination chemotherapy in the treatment of
advanced Hodgkin's disease. Ann Intern Med 73, 881-895.
DeVita, V.T., Jr., Simon, R.M., Hubbard, S.M., Young, R.C., Berard, C.W., Moxley, J.H., 3rd, Frei, E., 3rd,
Carbone, P.P., and Canellos, G.P. (1980). Curability of advanced Hodgkin's disease with chemotherapy. Longterm
follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92, 587-595.
Diehl, V., Brillant, C., Engert, A., Mueller, R.-P., Eich, H.-T., Mueller-Hermelink, K., Herrmann, R., Markova,
J., Ho, A., Hiddemann, W., Doerken, B., Greil, R., Josting, A., and Pfistner, B. (2005). Recent Interim Analysis
of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early
Unfavorable Stage Hodgkin's Lymphoma [Abstract]. Blood 106, 816.
Diehl, V., Brillant, C., Engert, A., Wolf, J., Nogova, L., Mueller, R.-P., Eich, H., Mueller-Hermelink, H.K.,
Herrmann, R., Doerken, B., Kanz, L., Greil, R., and Pfistner, B. (2004). Reduction of Combined Modality
Treatment Intensity in Early Stage Hodgkin's Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG
[Abstract]. Blood 104, 1307.
Diehl, V., Franklin, J., Hasenclever, D., Tesch, H., Pfreundschuh, M., Lathan, B., Paulus, U., Sieber, M.,
Rueffer, J.U., Sextro, M., Engert, A., Wolf, J., Hermann, R., Holmer, L., Stappert-Jahn, U., Winnerlein-Trump,
E., Wulf, G., Krause, S., Glunz, A., von Kalle, K., Bischoff, H., Haedicke, C., Duehmke, E., Georgii, A., and
Loeffler, M. (1998). BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as
COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German
Hodgkin's Lymphoma Study Group. J Clin Oncol 16, 3810-3821.
Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R.,
Dorken, B., Muller-Hermelink, H.K., Duhmke, E., and Loeffler, M. (2003). Standard and increased-dose
BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348,
2386-2395.
Diehl, V., Haverkamp, H., Mueller, R.P., Eich, H.T., Mueller-Hermelink, H.K., Cerny, T., Markova, J., Ho, A.,
Kanz, L., Greil, R., Hiddemann, W., and Engert, A. (2008). Eight Cycles of BEACOPP Escalated Compared
with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without
Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12
Trial of the German Hodgkin Study Group (GHSG). ASH Annual Meeting Abstracts 112, 1558.
Diehl, V., Sieber, M., Ruffer, U., Lathan, B., Hasenclever, D., Pfreundschuh, M., Loeffler, M., Lieberz, D.,
Koch, P., Adler, M., and Tesch, H. (1997). BEACOPP: an intensified chemotherapy regimen in advanced
Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 8, 143-148.
Dietlein, M., Eich, H.T., Fuchs, M., Borchmann, P., Engert, A., and Kobe, C. (2010). PET beim Hodgkin-
Lymphom. Der Onkologe 16, 18-27.
Donaldson, S.S., Link, M.P., Weinstein, H.J., Rai, S.N., Brain, S., Billett, A.L., Hurwitz, C.A., Krasin, M., Kun,
L.E., Marcus, K.C., Tarbell, N.J., Young, J.A., and Hudson, M.M. (2007). Final results of a prospective clinical
trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin
Oncol 25, 332-337.
Dores, G.M., Metayer, C., Curtis, R.E., Lynch, C.F., Clarke, E.A., Glimelius, B., Storm, H., Pukkala, E., van
Leeuwen, F.E., Holowaty, E.J., Andersson, M., Wiklund, T., Joensuu, T., van't Veer, M.B., Stovall, M.,
Gospodarowicz, M., and Travis, L.B. (2002). Second malignant neoplasms among long-term survivors of
Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20, 3484-3494.
124